



March 2012

Volume 17 Numbers 5/6
pp. 183–278



Cover Story

The leading story of this issue of *Drug Discovery Today*, by Carmel J. Pezaro, Deborah Mukherji and Johann S. De Bono reviews the preclinical discovery and clinical development of abiraterone acetate and they outline the strategy of parallel translational research for the treatment of men with metastatic castration-resistant prostate cancer.

DRUG DISCOVERY TODAY

REVIEWS

POST SCREEN

- 194 Targeting the S and G2 checkpoint to treat cancer**
Tao Chen, Peter A. Stephens, Fiona K. Middleton and Nicola J. Curtin
- 203 Combining imaging and pathway profiling: an alternative approach to cancer drug discovery**
Neil O. Carragher, Valerie G. Brunton and Margaret C. Frame
- 215 Virotherapy – cancer targeted pharmacology**
Alison Tedcastle, Ryan Cawood, Ying Di, Kerry D. Fisher and Len W. Seymour
- 221 Abiraterone acetate: redefining hormone treatment for advanced prostate cancer**
Carmel J. Pezaro, Deborah Mukherji and Johann S. De Bono
- 227 New regulatory framework for cancer drug development**
Paul S. Jones and David Jones
- 232 Targeting cancer metabolism – aiming at a tumour's sweet-spot**
Neil P. Jones and Almut Schulze
- 242 HSP90 inhibition: two-pronged exploitation of cancer dependencies**
Jon Travers, Swee Sharp and Paul Workman
- 253 Predictive *in vivo* animal models and translation to clinical trials**
Natalie Cook, Duncan I. Jodrell and David A. Tuveson
- 261 Stratified medicine for cancer therapy**
Emily C. Shaw and Peter W.M. Johnson
- 269 Cancer cell senescence: a new frontier in drug development**
Claire J. Cairney, Alan E. Bilisland, T.R. Jeffry Evans, Jon Roffey, Dorothy C. Bennett, Masashi Narita, Christopher J. Torrance and W. Nicol Keith